If you have chronic obstructive pulmonary disease, or COPD, and your doctor has started talking about a breathing machine, or you are already using one and wondering whether it is the right type, this article is for you. The terminology can feel overwhelming, but understanding it doesn’t have to be.
COPD is the umbrella term for emphysema and chronic bronchitis. Both conditions progressively narrow the airways and trap air in the lungs. This causes two distinct problems: oxygen levels in the blood drop (a condition called hypoxemia), and carbon dioxide, the waste gas your body needs to expel, begins to build up (a condition called hypercapnia). Elevated CO2 makes the blood more acidic, which places chronic stress on the heart and brain.
In earlier stages of COPD, supplemental oxygen through a nasal cannula is often enough to manage low oxygen levels. But as the disease advances, adding more oxygen alone does not solve the carbon dioxide problem. Breathing support devices work differently: they physically help the lungs move air in and out, acting like a mechanical assist for breathing muscles that have become weakened or overworked. Understanding that distinction is key to understanding why different devices exist and why the right choice matters.
CPAP delivers one constant pressure throughout the entire breathing cycle, the same whether you are inhaling or exhaling. Its primary job is to keep the upper airway from collapsing during sleep, which is why it is the gold-standard treatment for obstructive sleep apnea. For COPD, however, CPAP has an important limitation: because it cannot vary with the breathing cycle, it provides little real assistance in clearing CO2 from the lungs. Worse, having to exhale against a fixed elevated pressure can actually make breathing harder for someone with already-obstructed airways.
CPAP does have a role in COPD but likely works best in a specific situation. For example, patients who have both COPD and obstructive sleep apnea. That combination, called overlap syndrome, is covered in its own section below.
BPAP uses two different pressure settings: a higher pressure when you inhale and a lower pressure when you exhale. The gap between those two pressures is called the pressure support, and it is what actively assists the breathing muscles on every breath. This two-level design is precisely suited to the physiology of COPD. The higher inhalation pressure helps fill stiff or weakened lungs, and the lower exhalation pressure makes it easier to breathe out without fighting the machine.
BPAP is the standard home device for COPD patients who need ventilatory support, and it has robust evidence supporting it. Clinical trials have shown that long-term home BiPAP can reduce hospital readmissions and, in some patients, meaningfully extend survival.
NIV is an advanced form of bilevel support with greater control over breathing rate and timing. NIV can typically be delivered via a Bilevel device; however it may also be provided through a home mechanical ventilator when additional advanced or complex features are required. These may include multiple preset programs, specialized modes such as Auto EPAP, or situations in which backup battery support is needed to ensure patient safety and continuity of therapy.
Its most important additional feature is a backup rate: if you are not breathing fast enough on your own, the device automatically delivers a breath. This makes NIV appropriate for situations where the patient cannot be relied upon to trigger every breath independently.
NIV is the first-line hospital treatment for acute COPD flares that cause respiratory failure, where starting it early has been shown to reduce the need for intubation and to lower mortality. It is also used at home for the most advanced cases of COPD, and in palliative settings as a comfort measure to relieve breathlessness.
Normal CO2 levels: No breathing device is typically needed yet. Inhalers, pulmonary rehabilitation, and possibly supplemental oxygen are the mainstays of treatment at this stage. Your doctor will monitor your CO2 through periodic arterial blood gas tests.
Elevated CO2, stable at home: This is the clearest indication for home BiPAP therapy. Gold-standard guidelines recommend it for patients with persistent daytime CO2 above roughly 52 to 55 mmHg. Clinical trials have shown that high-intensity BiPAP, designed to target substantial CO2 reduction, significantly cuts hospital readmission rates compared to oxygen therapy alone.
Acute COPD flare in hospital: NIV is the standard of care for acute hypercapnic respiratory failure. When started early during an admission, it can reduces the need for intubation. The benefit is greatest before the patient becomes exhausted from the sustained effort of breathing through a crisis.
End-stage or palliative COPD: NIV at home can serve as a comfort measure to relieve breathlessness even when the goal of care has shifted toward quality of life rather than disease modification. These conversations are an important part of advance care planning and are best had with your care team before a crisis arises.
Roughly one in five COPD patients also has obstructive sleep apnea. When the two conditions coexist, the combination is called overlap syndrome, and it is more dangerous than either condition alone. During sleep, the oxygen drops caused by sleep apnea are deeper and more prolonged in someone whose lungs are already compromised by COPD. This raises the risk of pulmonary hypertension, right heart failure, and death significantly above the risk carried by either condition in isolation.
Treatment depends on which problem is predominant. If sleep apnea is the dominant issue and daytime CO2 is normal, CPAP may be sufficient to prevent the overnight oxygen dips and their cardiovascular consequences. If CO2 is elevated, which is common in overlap syndrome, BiPAP is strongly preferred: it both holds the airway open the way CPAP does and actively assists ventilation to clear the excess CO2.
A formal sleep study is needed to diagnose overlap syndrome properly. If you snore heavily, have been observed stopping breathing during sleep, feel unrefreshed after a full night's rest, or wake with morning headaches, raise it with your doctor.
The starting point is often an arterial blood gas (ABG) test, a small blood draw usually taken from the wrist, which measures your oxygen and CO2 levels with precision. This single test is a very important piece of information in the device-selection process. Spirometry results, particularly your FEV1 (the volume of air you can force out in one second), classify the severity of your airflow obstruction and help predict future risk. Your symptom burden, recent hospitalization history, and sleep patterns all factor in alongside the numbers.
Starting BiPAP is not a final or irreversible commitment. A trial period, typically with repeat blood gas testing after four to twelve weeks, lets your team confirm the device is working and fine-tune the pressure settings. Adherence matters enormously. Research suggests at least five to six hours of nightly use is needed to achieve meaningful CO2 clearance. Modern devices record usage data automatically, which your care team can review at follow-up appointments. If you are struggling to reach that threshold, say so, as there are often mask adjustments and setting changes that can help.
Mask fit is a very significant predictor of whether patients stick with therapy long enough to benefit from it. There are three main mask types: nasal masks that cover just the nose, nasal pillow masks with small inserts that sit at the nostrils, and full-face masks that cover both nose and mouth. Each suits different people and different pressure requirements. If your current mask is uncomfortable, leaking, or causing skin irritation, ask your device supplier about alternatives before concluding that the therapy itself does not work for you.
A heated humidifier, built into most modern BiPAP and NIV units, prevents the airway dryness that makes sustained high-pressure therapy unpleasant, particularly at higher settings. Use it consistently and adjust the humidity level for your comfort and local climate.
What is my current CO2 level, and how has it changed over time?
Is my CO2 elevation happening mostly overnight, or during the day as well?
Should I have a sleep study to check for overlap syndrome?
What pressure settings are you starting with, and what are we trying to achieve?
How will we measure whether the therapy is working, and over what timeframe?
What should I do if I cannot tolerate the mask or the pressure?
CPAP is an effective, well-proven treatment for obstructive sleep apnea but cannot adequately address the CO2 retention problem at the core of COPD on its own. BiPAP is the standard home treatment for COPD patients with elevated CO2, supported by solid and growing clinical evidence. NIV is a more capable form of bilevel support used in hospitals during acute respiratory failure and at home for the most advanced cases.
The right choice depends on many different factors, including the gas in your blood, the severity of your airflow obstruction, and whether sleep apnea is also present. It is not a decision to make based on cost alone or on what a neighbor happens to use. The best path is a thorough evaluation by a respiratory physician who can match the device to your individual physiology and then follow up to make sure no adjustments need to be made.
References
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for COPD: 2024 Report. goldcopd.org
Kohnlein T, et al. Non-invasive positive pressure ventilation for severe stable COPD. Lancet Respir Med. 2014;2(9):698-705.
Struik, F M et al. “Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis.” Respiratory medicine vol. 108,2 (2014): 329-37. doi:10.1016/j.rmed.2013.10.007
Marin, Jose M et al. “Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome.” American journal of respiratory and critical care medicine vol. 182,3 (2010): 325-31. doi:10.1164/rccm.200912-1869OC
Ergan, Begum et al. “European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD.” The European respiratory journal vol. 54,3 1901003. 28 Sep. 2019, doi:10.1183/13993003.01003-2019
Murphy PB, et al. Home NIV with oxygen vs oxygen alone after acute COPD exacerbation. JAMA. 2017;317(21):2177-2186.
LEGAL DISCLAIMER: Material in this newsletter is provided for general health education and informational purposes and to provide references to other resources only; it may not apply to you as an individual. While Apria Healthcare believes that the information provided through this communication is accurate and reliable, Apria Healthcare cannot and does not make any such guarantee. It is not intended to be a replacement for professional medical advice, evaluation, diagnosis, services or treatment (collectively, “medical treatment”). Please see your healthcare provider for medical treatment related to you and your specific health condition(s). Never disregard medical advice or delay seeking medical care because of something you have read on or accessed through this website. Reading this newsletter should not be construed to mean that you have a healthcare provider/patient relationship.